A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
a study on Solid Tumor
Locally Advanced Solid Tumors Metastatic Solid Tumors ALK ROS1 NTRK Sarcoma Lung Neoplasms Carcinoma, NSCL NSCLC Non Small Cell Lung Thyroid Disease Colonic Neoplasms Thyroid Neoplasms Carcinoma, Neuroendocrine Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Disease Respiratory Tract Disease Carcinoma, Bronchogenic Bronchial Neoplasms Endocrine System Disease Colorectol Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Gastrointestinal Disease Colonic Disease Intestinal Disease Endocrine Gland Neoplasms Head and Neck Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Adenocarcinoma Non Small Cell Lung Cancer Solid Tumors Rearrangements TRIDENT-1 TKI TKI naive TKI pretreated Anti-tumor activity Repotrectinib Advanced Solid Malignancies Oral repotrectinib (TPX-0005) Repotrectinib (TPX-0005)
Lead Scientists at UC Health
- Samuel Ejadi, M.D. (uci)
Associate Clinical Professor, Medicine. Authored (or co-authored) 9 research publications
- Lyudmila Bazhenova, M.D. (ucsd)
Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators.
- accepting new patients
- Start Date
- Completion Date
- Turning Point Therapeutics, Inc.
- Phase 1/2
- Study Type
- Last Updated